Ojemda (Tovorafenib) Patent Expiration, LOE Window & CMS Spending
Ojemda (Tovorafenib) by Day One Biopharmaceuticals: FDA Orange Book core substance LOE 2031-08-04 (last listed 2035-06-23), 0 AB generics, $20.2M 2024 CMS Part D & Medicaid spend, and $33,916 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Day One Biopharmaceuticals |
| FDA Application & Pathway | N217700 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2031-08-04 |
| Last Listed Patent or Exclusivity Date | 2035-06-23 |
| Orange Book Patents (*PED Extensions) | 2 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $20.2M |
| 2024 Medicare Part D Spend | $705K |
| 2024 Medicaid Spend | $19.5M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($33,916 intro WAC) |